Finance

Codon adds Roche Venture’s Mutz to team to capitalize therapeutic, synthetic bio start-ups

After seven years of making angel investments with founder and former CMEA Managing Director Karl Handelsman as its sole LP, San Francisco-based VC Codon Capital has brought Mitchell Mutz on board to ramp up early...

F2G raises $60.8M to get new class of antifungal to market

F2G thinks its latest round of venture funding should be enough to carry its lead product onto the market, where it could become the first new antifungal in two decades, according to the company. New...

AI play Atomwise to build internal pipeline with $123M series B

After building and validating its AI-driven small molecule discovery platform through partnerships, Atomwise has raised a $123 million series B round that will enable the company to begin building its own pipeline.  Since its 2012...

Aug. 10 Quick Takes: Megarounds for Lepu, Dyne; plus CureVac’s IPO plans, top marks for Chinese biotech trio and more

Riverhead, Ping An lead Lepu’s megaround Lepu Biotechnology Co. Ltd. raised RMB1.3 billion ($185.3 million) in a series B round jointly led by Riverhead Capital and Ping An Capital, with participation by Haitong Innovation Capital Management,...

Freeline, Checkmate make NASDAQ debuts as 2020 pads its record-setting IPO tally

NASDAQ debuts by Syncona gene therapy company Freeline and Checkmate, a cancer company co-founded by Art Krieg, pushed the year’s IPO haul to $14.7 billion, more than double the amount raised over the same period...

Aug. 6 Quick Takes: More pressure on China’s U.S. listings; busy Editas; Athenex bestows royalty on Sagard; Longwood, CFF launch incubator and more

Trump admin plan would pressure U.S.-listed Chinese companies A Trump administration working group plan has recommended that Chinese companies listed on a U.S. stock exchange provide the Public Company Accounting Oversight Board with access to...

‘Not drip-feeding’: Andera looks to deploy record €450M fund to mostly European biotechs

Next year Andera aims to join the ranks of European life science VCs raising record funds with the close of its largest fund to date at €450 million. Andera Partners’ Olivier Litzka said the firm...

Led by AveXis vets, Taysha adds dry powder ahead of first clinical trials for CNS gene therapy pipeline

Less than four months after launching with $30 million, Taysha has closed a $95 million series B to advance its lead CNS gene therapy programs into the clinic and build a commercially scalable GMP manufacturing...

Data Bytes: led by ex-U.S. biopharmas, July follow-ons bring in $5.8B

July saw $5.8 billion in follow-on capital raised across 36 biopharma offerings, bringing the year’s total so far to $28 billion. Two of the month’s three largest follow-ons came from companies based in China. Shanghai...

Interest in protein degradation runs hot as Kymera files for IPO

Atlas-backed Kymera has at least one comparator among preclinical protein degradation companies as it seeks a NASDAQ listing -- and it could soon be followed by another company in the same category. A regulatory filing...

After raising crossover-heavy $70M round, p53 play PMV likely one of the next preclinical IPOs

PMV’s $70 million series D round included multiple crossover investors, a sign the biotech will join the rush of preclinical companies lining up for an IPO this year. Crossover investors are the most prolific backers...

Gilead expects remdesivir to drive P&L rebound by year-end

Gilead bumped up its full year guidance Thursday after projecting to manufacture 2 million treatment courses of its COVID-19 antiviral remdesivir by year-end, and sell 1-1.5 million courses even as the company reported 2Q20 earnings...

AlloVir carries July’s IPO haul beyond $2.5B

AlloVir, the month’s final biotech to conduct a NASDAQ IPO, became the latest to reach a 10-digit valuation, based on a first-day stock gain of 49% that drove its market cap to more than $1.5...

Polyphor gains financial cushion ahead of Phase III readout of lone clinical program

A new equity financing should give Polyphor a little more financial breathing room as the Swiss biotech tries to broaden its pipeline and move away from an all-or-nothing Phase III coin flip in 1Q21. Polyphor...

Data Bytes: Thrive megaround pours more cash into early cancer detection

Thrive’s $257 million series B round continues a trend of investors seeing big value in liquid biopsy tests for early cancer detection, a stark contrast to the historic undervaluing of diagnostics. Launched last year with...